Worth $15 billion this year, what will it be worth in 2007?

What impact will the continued success of the proton pump inhibitors have?

These are just some of the questions this in-depth reports answers for you.

Over 150 pages packed full of cutting edge information

Packed full of tables, charts and graphs

Previously unmet need in the drug market for inflammatory bowel disease (Crohn’s and ulcerative colitis) and irritable bowel syndrome (IBS) is being tackled by a number of pharmaceutical companies. Advanced therapies in both areas have recently been launched and research and development will in the next couple of years yield further advancements. The IBS market, which only recently has seen the advent of IBS-specific therapies, will grow at an average rate of 31% over the next five years.

The Gastrointestinal Market 2003 is arranged to provide an overview of this massive and ever-dynamic market. Specific attention is given to the following major disorders and the current and future pharmaceutical products indicated for their treatment:

Gastroesophageal Reflux Disease (GERD)

Crohn’s disease

Ulcerative colitis

Irritable Bowel Syndrome

Peptic Ulcer Disease

Included in this report are special visiongain Analysis sections which discuss and analyze financial trends, and the major issues effecting them, such as patent expirations, new indications, generic competition, and blockbuster drugs, such as AstraZeneca’s Nexium and Centocor/Schering’s Remicade.

Overviews of the various disorders, including their causes, pathologies, symptoms, and treatment alternatives are provided in order to provide proper context to the pharmaceutical market governing the particular disorder. Information on leading therapies and market analysis of emerging therapies is presented, including those in the following classes:

Proton Pump Inhibitors

H2 Receptor Antagonists

Monoclonal Antibodies

Serotonin-4 Receptor Agonists

Cholecystokinin Type A (CCKA) Receptor Antagonists

Detailed financial information and forecasting is also provided for each chapter including in-depth coverage of drugs such as:

Nexium

Prilosec

Remicade

Zelnorm

Prevacid

Analysis includes the use of charts and graphs measuring product growth and trends within the gastrointestinal marketplace. Company-specific information, including sales figures, drug pipeline status, and research and development trends is provided throughout the report. Five-year financial forecasts are also provided.

Order this report NOW to ensure your continued success in this growing market.

- PRICING -

Individual report pricing - single user copies of this report are available for only US$1649.00. Allow your whole company to have access to this information for only the price of 4 copies. Company-wide License (CD Rom) for only US$6595.00.

Format: CD ROM